Last reviewed · How we verify
Bravelle and Menopur
At a glance
| Generic name | Bravelle and Menopur |
|---|---|
| Sponsor | Main Line Fertility Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Continuous Double Ovarian Stimulation. (PHASE4)
- Hormone Evaluation in Artificial Reproductive Technology (NA)
- Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study (PHASE4)
- C677T Methylenetetrahydrofolate Reductase Mutation
- Single Dose FSH-GEX™ in Healthy Volunteers (PHASE1)
- Multiple Dose FSH-GEX(TM) in Healthy Volunteers (PHASE1)
- Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF (PHASE1, PHASE2)
- FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bravelle and Menopur CI brief — competitive landscape report
- Bravelle and Menopur updates RSS · CI watch RSS
- Main Line Fertility Center portfolio CI